60
Participants
Start Date
September 28, 2018
Primary Completion Date
December 9, 2021
Study Completion Date
August 1, 2024
Pembrolizumab
Pembrolizumab is a drug (an antibody) that may treat cancer by working with the immune system
Bevacizumab
"Bevacizumab (also known as Avastin) is designed to prevent or slow down the growth of cancer cells by blocking the growth of blood vessels."
Re-irradiation
Radiotherapy destroys cancer cells using radiation aimed at a cancer from a machine
Columbia University / Herbert Irving Comprehensive Cancer Center, New York
Hospital of the University of Pennsylvania, Abramson Cancer Center, Philadelphia
Beth Israel Deaconess Medical Center, Boston
Dana Farber Cancer Institute, Boston
Massachusetts General Hospital, Boston
Merck Sharp & Dohme LLC
INDUSTRY
Dana-Farber Cancer Institute
OTHER